PO.CL01.14 · 临床研究
利用AI驱动的端到端工作流程对膀胱癌中抗体-药物偶联物靶点进行空间解析的多重免疫荧光分析
Spatially resolved multiplex immunofluorescence profiling of antibody-drug conjugate targets in bladder cancer using an AI-powered end-to-end workflow
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:膀胱癌是最常见的恶性肿瘤之一,具有显著的发病率和死亡率。新兴的抗体-药物偶联物(ADC)是这一棘手疾病有前景的治疗选择。然而,需要了解不同ADC靶分子的位置和存在情况以指导治疗决策。多重免疫荧光(mIF)提供了同时研究多种生物标志物及其空间分布的机会,从而实现对组织切片内ADC靶点的详细空间分析。
方法:我们利用一种新型mIF试剂系统,通过对临床相关的ADC靶分子进行染色,分析来自一个患者队列的福尔马林固定石蜡包埋(FFPE)膀胱癌样本。切片使用ZEISS Axioscan 7空间生物学系统和SlideStream自动化进行成像,以实现高通量、标准化的采集。图像分析使用整合到自动化工作流程中的Mindpeak PhenoScout进行,该软件采用预训练的AI模型进行组织区域分割、单细胞检测、生物标志物阳性判定,以及基于多通道信号整合的表型分类。
结果:我们建立了一种mIF检测方法,用于研究膀胱癌样本中不同的ADC靶点。这一信息结合基于AI的分析,被用于为每位患者生成ADC敏感性谱。
结论:膀胱癌的空间解析mIF分析揭示了临床相关的生物标志物特征,凸显了其用于患者分层的潜力。自动化成像与AI驱动分析的整合确保了稳健、可重复的空间分析,加速了多重组织成像向精准肿瘤学和个性化治疗方法的转化。
查看英文原文 English abstract
Background: Bladder cancer is one of the most common malignancies, with significant morbidity and mortality rates. Emerging antibody-drug conjugates (ADC) are promising treatment options for this challenging disease. However, insight about the location and presence of different ADC target molecules is needed to guide treatment decisions. Multiplex immunofluorescent (mIF) offers the opportunity to investigate multiple biomarkers and their spatial distribution at the same time, enabling detailed spatial analysis of ADC targets within a tissue section.
Methods: We utilized a novel mIF reagent system to analyze formalin-fixed, paraffin-embedded (FFPE) bladder cancer samples from a patient cohort by staining clinically relevant ADC target molecules. Slides were imaged using the ZEISS Axioscan 7 spatial biology system and SlideStream automation for high-throughput, standardized acquisition. Image analysis was performed using Mindpeak PhenoScout integrated to the automated workflow, which employs pre-trained AI models for tissue region segmentation, single cell detection, biomarker positivity, and phenotype classification based on multichannel signal integration.
Results: We established an mIF assay to investigate different ADC targets in bladder cancer samples. This information, in combination with AI-based analysis, was used to generate an ADC sensitivity profile for each patient.
Conclusions: Spatially resolved mIF analysis of bladder cancer revealed clinically relevant biomarker signatures, highlighting its potential for patient stratification. The integration of automated imaging and AI-driven analysis ensures robust, reproducible spatial profiling, accelerating the translation of multiplex tissue imaging into precision oncology and personalized treatment approaches.
利益披露 Disclosure
C. Kuppe, None..
S. Samiei, None..
K. Dornblut, None..
F. Schneider, None..
M. Widmaier, None..
F. Leiss, None.